When Big Pharma Breaks the Law—Prosecute the CEO

Since 2004, pharma has paid over $7 billion in fines and penalties, but even these figures barely dent profits. The $2.3 billion fine Pfizer paid in September 2009 for the way one of its subsidiaries marketed Bextra, the non-steroidal anti-inflammatory drug, and three other drugs, was the biggest ever paid by a corporation in the US. Yet the fine was just 14 per cent of $16.8 billion revenue from the drugs from 2001 to 2008, little more than the price of doing business.

Doctors draw payments from drug companies: Physicians say presentations they make are educational, but critics say the practice puts financial rewards ahead of patient care

Follow drug company money in Illinois, and it leads to the psychiatry department at Rush University Medical Center, a prominent headache clinic on the North Side of Chicago, a busy suburban urology practice and a psychiatric hospital accused of overmedicating kids.

In each of these settings, doctors are drawing an extra paycheck — worth tens of thousands of dollars a year or more — for speaking to other medical professionals about pharmaceutical products at company-sponsored, company-scripted events in Illinois and across the country.

Prescription for prestige—Drug firms’ speaking fees flow to Harvard doctors; concerns about influence prompt new restrictions

Dr. Brent Forester, a geriatric psychiatrist at McLean, was one of the Massachusetts physicians paid the most last year, when he made $73,100 for giving nearly 40 talks for Eli Lilly to colleagues about the antipsychotic Zyprexa and the antidepressant Cymbalta over dinners in restaurants and in doctors offices. He has resigned from speakers bureaus to comply with the new rules, but said he “never felt like a spokesperson for the company at all.’’

Pfizer ends trial after widespread overdosing of children with psych drug

Drug giant Pfizer has canceled a scheduled clinical trial of its antipsychotic drug Geodon after the FDA accused it of subjecting child participants in a prior study to “widespread overdosing.”

$257 Million Lawsuit Award Against Antipsychotic Drug Maker: One of the largest in the history of the state & expected to set nationwide precedent

The award came late Thursday evening in a case involving the drug Risperdal, a popular antipsychotic administered for the treatment of schizophrenia and bipolar disorder manufactured by Janssen, a division of Ortho-McNeil-Janssen Pharmaceuticals Inc., which is part of Johnson & Johnson. The jury, which has been hearing the case for almost two months, found the firm misled Louisiana doctors about the possible side effects of the drug.

CCHR International

News